SCHEMBL1665264

SCHEMBL1665264

CCOC(=O)c1ccc(N2CCC(C(N)=O)CC2)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
GAA P10253 2/20 0.54
MAPT P10636 10/20 0.54
HPGD P15428 5/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 4/20 0.51
NPC1 O15118 3/20 0.51
TSHR P16473 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
LMNA P02545 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
KDM4E B2RXH2 1/20 0.49
RAB9A P51151 3/20 0.47
PRMT1 Q99873 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31467934 0.85 L3MBTL1 (0.56) L3MBTL1GAAMAPTHPGDSMN1; SMN2
SCHEMBL1665681 0.83 L3MBTL1 (0.57) L3MBTL1GAAMAPTHPGDSMN1; SMN2
SCHEMBL21668771 0.82 MAPT (0.55) L3MBTL1GAAMAPTHPGDSMN1; SMN2
SCHEMBL14804173 0.82 GAA (0.50) L3MBTL1GAAMAPTHPGDSMN1; SMN2
SCHEMBL1665672 0.81 MAPT (0.53) L3MBTL1GAAMAPTHPGDSMN1; SMN2
SCHEMBL3918983 0.81 L3MBTL1 (0.59) L3MBTL1GAAMAPTHPGDMEN1
SCHEMBL23965738 0.81 MAPT (0.53) L3MBTL1GAAMAPTHPGDSMN1; SMN2
SCHEMBL21668775 0.81 MAPT (0.53) L3MBTL1GAAMAPTHPGDSMN1; SMN2
SCHEMBL23582930 0.80 HTT (0.55) GAAMAPTHPGDSMN1; SMN2MEN1
SCHEMBL9832356 0.76 L3MBTL1 (0.54) L3MBTL1GAAMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2314586-B1 2-Acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC (JP) 2016-09-14 EP disclosed
EP-2314586-B1 2-Acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC (JP) 2016-09-14 EP disclosed
US-8765764-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2014-07-01 US disclosed
US-8765764-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2014-07-01 US disclosed
EP-1466912-B1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2013-04-24 EP disclosed
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA, INC. (JP) 2013-03-28 US disclosed
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA, INC. (JP) 2013-03-28 US disclosed
US-8338429-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2012-12-25 US disclosed
US-8338429-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2012-12-25 US disclosed
EP-2314586-A1 2-Acylaminothiazole derivative or salt thereof Astellas Pharma Inc. (JP) 2011-04-27 EP disclosed
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed
US-7638536-B2 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally ASTELLAS PHARMA INC. (JP) 2009-12-29 US disclosed
US-7638536-B2 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally ASTELLAS PHARMA INC. (JP) 2009-12-29 US disclosed
US-20050153977-A1 2-Acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2005-07-14 US disclosed
EP-1466912-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153977-A1 2-Acylaminothiazole derivative or salt thereof MPL, JAK2, ABL1 L3MBTL1 1136/4885GAA 3757/4885MAPT 4550/4885
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 L3MBTL1 1136/4885GAA 3757/4885MAPT 4550/4885
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 L3MBTL1 1136/4885GAA 3757/4885MAPT 4550/4885
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 L3MBTL1 1136/4885GAA 3757/4885MAPT 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.